Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Corporate Alexis Vandier appointed new Chief Executive Officer to guide the Company through its next phase of growth Strategy focused on leveraging both the Company's clinical portfolio
The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.
OSE Immunotherapeutics Appoints its International Scientific Advisory Board pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.